Q: Why can't you do this kind of work in a zoo or sanctuary?

A: The work we do requires a lot of time and effort. You need to be able to collect many samples of the same behavior. Animals in zoos and sanctuaries are notoriously unwilling to do what we want them to. Hercules and Leo do everything for a grape or a cherry or a bit of juice.

Q: What are their living conditions?

A: We have a very large facility. It's the equivalent of three moderate-sized bedrooms that are adjacent to each other. They have hammocks, ropes for climbing, and magazines to tear up. We have an animal handler whose job is to keep them comfortable and stimulated. She

hides treats in cardboard boxes and gives them plastic toys like airplanes to play with. We try to make their day-to-day lives as interesting as possible. We don't want them to feel threatened or frightened; otherwise we wouldn't get reliable results.

Q: How do you view your relationship with them? A: I interact with them

weekly, but the animal

handler has the most direct contact with them. I don't have the bond with them that the animal handler does; she loves them and loves spending time with them. I see them as collaborators, as willing participants in the project. And I respect them. I would never ask them to ride a bicycle or anything goofy like that.

Q: How have perceptions of animal research changed in the decades you have been working with primates?

A: There has been a sea change in attitudes towards chimpanzee research. Oversight has become much stricter, and getting approval to do this work has been harder. The space we have used to be considered vast for these animals; now it's considered average.

In the past, this research wasn't considered controversial; my colleagues used to appear on television programs to talk about their work. Now, my university is very reticent to talk about this research at all. I've been consistently advised never to respond to reporters, even though I don't think there's anything that needs to be concealed. I'm very proud of the work we do, and I feel comfortable with the procedures

we use. They worry about us being targeted by animal rights activists, so they think it's better to say nothing than to say something that could be used against you.

O: What do you make of the movement to turn chimpanzees into legal persons?

A: I think giving them personhood status is a sham. If anyone treats them like people, it's us. We don't treat them like prisoners; we only work with them when they're willing. But we have to be cognizant that these are chimpanzees-not people. They can't provide for themselves; they need human care and protection. They are remarkable animals, and we should respect what they are and what they need. You don't have to pretend

> something is a person to treat it justly.

Q: How has the litigation affected you?

A: Stony Brook is keeping me out of it. It hasn't changed our protocols, but the university has scrutinized us much more closely. They're not happy about it. I find a lot of what the other side is saying very untrue and hurtful. It's upsetting when someone calls you an

evil scientist, or when they say we're causing pain or needless suffering. It's strange to hear people talking about these animals when they don't know who they are.

Q: What's next for Hercules and Leo?

A: Our project is winding up in the next few weeks. After that, it's New Iberia's decision what to do with them. They've said they intend to retire them to a sanctuary. After that, our facility will go dormant.

Q: What do you see as the future of chimp research?

A: The U.S. Fish and Wildlife Service is considering classifying both captive and wild chimpanzees as endangered. NIH [the National Institutes of Health] is saying they're not as useful as animal models. Grant money is very hard to come by, and it's becoming increasingly difficult to meet the regulatory standards. Pretty soon, the kind of work I do will not be possible anymore. We're going to end up with chimpanzees completely cut off from humans; they'll become alien beings. And that makes me sad, because I think there are still a lot of things we can learn from them.

MOLECULAR EPIDEMIOLOGY

HIV family trees reveal viral spread

New studies could aid public health efforts

By Jon Cohen

he very trait that makes HIV so good at dodging the immune system-and at thwarting efforts to develop an effective vaccine-might also turn out to be an Achilles' heel.

HIV evades immune attack by copying itself at breakneck speed, regularly mutating so that each progeny differs slightly from the parent virus. The pace of change means that the more closely two isolates resemble each other, the more recently they shared a common hostmaking it possible to track the spread of the virus and design precise interventions to block it. Last week at the New York Academy of Sciences in New York City, researchers, public health specialists, and HIV/AIDS advocates discussed how to exploit the potential of the technique, called phylogenetic analysis-and the thorny ethical and legal issues it raises.

"This is a methodological breakthrough," says epidemiologist William Blattner of the University of Maryland School of Medicine's Institute of Human Virology in Baltimore. The plummeting costs of DNA and RNA sequencing are now allowing it to be applied on a large scale, and early efforts are yielding some surprises about how HIV spreads and when it can most effectively be controlled.

At the heart of the technique is the assumption that if the HIV sequences found in two people differ by less than 1.5%, then they are in a "transmission cluster." This does not prove that one person infected the other-there could have been intermediaries-but their infections are closely linked. Because HIV mutates at a constant rate, researchers can also construct a molecular clock to estimate when the transmission took place. Combining the information from many HIV-infected people in a limited geographical area creates diagrams that resemble airline routing maps, allowing researchers to infer the direction and speed of spread.


DEMES

One study, by a group led by epidemi-



a locomotion experiment.





UCSD's Davey Smith and co-workers created an HIV transmission network map, shown here in December 2014, from 15 years of sequence data.

ologist Alexa Oster of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, takes advantage of a CDC recommendation that before starting antiretroviral (ARV) treatment, every newly infected person be tested for drug-resistant virus. That requires sequencing HIV, which has enabled CDC to build an anonymized database that includes information such as likely mode of transmission and age.

With researchers from the University of California, San Diego, Oster's team mined HIV sequences from 27 sites around the country. They found that in men who report having sex with men (MSM), that explains the transmission 88% of the time. But surprisingly, Oster said, among men and women who inject drugs, the most common source of infection is not needle sharing but sex involving MSM. Also unexpected: Infections in heterosexual women were more frequently linked to MSM than to heterosexual men.

CDC is now tracking transmission networks of 30 or more people to project whether they will grow by 2020. "If we were able to predict which clusters are going to grow, we would know where we might want to focus prevention efforts," Oster said.

Christophe Fraser, an epidemiologist at Imperial College London, and his colleagues hope to bolster prevention efforts in the Netherlands with their analysis of more than 13,000 HIV sequences from a cohort of predominantly MSM. They identified 106 distinct transmission networks and 883 probable transmitters, 69.2% of whom had undiagnosed infections; diagnosed people on ARV treatment, in contrast, rarely transmitted. What's more, 40% of the probable transmitters had just recently become infected, a time when they are most infectious. Models suggest that treating high-risk people who test negative for HIV with ARVs, a strategy called preexposure prophylaxis, could lead to "substantial reductions in transmission" in the Netherlands, Fraser said.

An ambitious new consortium, the Phylogenetics and Networks for Generalised HIV Epidemics in Africa (PANGEA_HIV), plans to sequence 20,000 full HIV genomes from people who are already participating in other research studies in four sub-Saharan countries. PANGEA_HIV aims to see whether phylogenetics can accurately assess new infection rates. That, in turn, could reveal whether a prevention intervention worked. "If you can use genetic data to see the effect of interventions, it may be much cheaper" than the current method of following an uninfected cohort over time, said PANGEA_HIV collaborator Tulio de Oliveira, a bioinformatics specialist at the Wellcome Trust Africa Centre for Health and Population Studies in Mtubatuba, South Africa.

Speakers stressed the limits of phylogenetic analyses and cautioned that data could potentially be misused. Gay men could be "blamed" for infecting heterosexual women, for example. Several countries criminalize HIV transmission and homosexuality, and some speakers worry that governments could try to acquire confidential information to identify individuals in the studies. "Using this technology does not prove who infected whom: It proves that people were involved in a temporally related transmission cluster," stressed Mark Harrington of Treatment Action Group in New York City. "We don't want to have a bunch of court cases where people are suing because they have biologically similar strains." ■

PHOTO



HIV family trees reveal viral spread

Jon Cohen

Science **348** (6240), 1188-1189. DOI: 10.1126/science.348.6240.1188

ARTICLE TOOLS

http://science.sciencemag.org/content/348/6240/1188

PERMISSIONS

http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the Terms of Service

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The title *Science* is a registered trademark of AAAS.